Voriconazole

Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response

Retrieved on: 
Friday, March 22, 2024
Nephrotoxicity, Urinary tract infection, Fungal infection, Culture, Ventilator-associated pneumonia, Burns, Internal medicine, Amphotericin B, Emphysema, Azole, Coronary artery disease, Debridement, Carcinoma, Risk, Hyperlipidemia, Patient, Lung, LNC, Fusarium, Female, Malignancy, University, Doctor of Philosophy, MD, Aspergillosis, Echinocandin, Fever, Immune system, Division, Hypertension, Voriconazole, Physician, Infection, Pharmaceutical industry

The successful MAT2203 treatment outcome in these patients therefore adds to our confidence for the upcoming ORALTO Phase 3 trial in patients suffering from invasive aspergillosis with limited treatment options.

Key Points: 
  • The successful MAT2203 treatment outcome in these patients therefore adds to our confidence for the upcoming ORALTO Phase 3 trial in patients suffering from invasive aspergillosis with limited treatment options.
  • She was transitioned to oral MAT2203 for two weeks, which led to clinical resolution of her fungal infection.
  • She began to show clinical improvement following two weeks of oral MAT2203 treatment and her skin wounds completely healed following six months of MAT2203 treatment.
  • “MAT2203 continues to demonstrate its potential to effectively treat invasive fungal infections and help patients achieve complete clinical resolution.

TFF Pharmaceuticals Announces Update on Clinical Programs

Retrieved on: 
Wednesday, March 20, 2024
Health, TFF, P-value, Acceleration, Partnership, Patient, IPA, EAP, KOL, Mortality, Clinical research associate, Microsoft Access, Calendar, Potential, Safety, Voriconazole, Pharmaceutical industry

FORT WORTH, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, is announcing data updates and strategic prioritization of its clinical programs. Based on positive data from the ongoing Phase 2 study of TFF TAC, the potential to address a significant unmet need in lung transplant medicine, and substantial market opportunity, the Company has made the decision to prioritize the TFF TAC program and focus resources on the acceleration of its clinical pathway towards registration.

Key Points: 
  • “However, after a rigorous assessment of our pipeline, including the significant capital and resources required to progress both clinical development programs, we will focus our clinical development efforts and financial resources on TFF TAC.
  • In summary, for TFF TAC, eight out of eight patients have successfully transitioned from oral Tacrolimus to TFF TAC in the Phase 2 study.
  • TFF TAC continues to demonstrate favorable safety results with no mortality or discontinuations due to adverse events.
  • The Company will host a conference call on Wednesday, March 27, 2024, at 4:30 PM Eastern Time, to discuss updated clinical data for the TFF TAC and TFF VORI.

TFF Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 15, 2023
COPD, Insurance, Calendar, British Aerospace EAP, EAP, Conference call, TFF, SARS-CoV-2, SBIR, National Institute of Allergy and Infectious Diseases, Clinical trial, CRADA, Pharmacokinetics, G&A, Voriconazole, Temperature, Respiratory syncytial virus, Bangladesh Technical Education Board, Medication, Research and development, DARPA, ET, RSV, Patent, Patient, Chronic pulmonary aspergillosis, Administration, NIEHS, Roflumilast, Corporation, PPB, NIAID, R, Leidos, General Administration of Sport of China, Conference, Infection, Pharmaceutical industry, Vaccine, Fine chemical, Security (finance), Cryptocurrency

“We continue to make solid progress in our Phase 2 trials of TFF VORI and TFF TAC and expect to announce initial data by the end of 2023,” said Dr. Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals.

Key Points: 
  • “We continue to make solid progress in our Phase 2 trials of TFF VORI and TFF TAC and expect to announce initial data by the end of 2023,” said Dr. Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals.
  • We’ve also launched our EAP for TFF VORI and partnered with Durbin to implement the program across several countries.
  • For the quarter ended June 30, 2023, compared to quarter ended June 30, 2022
    Cash Position: as of June 30, 2023, TFF Pharmaceuticals reported cash and cash equivalents of $7.7 million.
  • Net Loss: TFF Pharmaceuticals reported a net loss for the second quarter of 2023 of $5.0 million, compared to a net loss of $8.7 million for the comparable period in 2022.

TFF Pharmaceuticals Inc. and Uniphar Durbin Ireland Ltd. Announce the Opening of an Expanded Access Program for Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Pulmonary Aspergillosis and Other Voriconazole Responsive Fungal Pulmonary Infec

Retrieved on: 
Monday, July 31, 2023
Partnership, EAP, TFF, Expanded access, Aspergillus, Clinical trial, Voriconazole, Allergic bronchopulmonary aspergillosis, Chronic pulmonary aspergillosis, IPA, Patient, Microsoft Access, Special access program, Pharmaceutical industry

The Expanded Access Program covers pulmonary aspergillosis including invasive pulmonary aspergillosis, chronic pulmonary aspergillosis, allergic bronchopulmonary aspergillosis, aspergillus tracheobronchitis, and aspergillus bronchoanastomotic infections as well as other voriconazole responsive fungal pulmonary infections.

Key Points: 
  • The Expanded Access Program covers pulmonary aspergillosis including invasive pulmonary aspergillosis, chronic pulmonary aspergillosis, allergic bronchopulmonary aspergillosis, aspergillus tracheobronchitis, and aspergillus bronchoanastomotic infections as well as other voriconazole responsive fungal pulmonary infections.
  • Uniphar Durbin Ireland Limited has been appointed to implement TFF Pharmaceutical’s Expanded Access Program in the United States, Australia, United Kingdom, Canada, and within select countries in Europe.
  • “We are pleased to be working with Durbin to offer the Expanded Access Program for TFF VORI,” said Dr. Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals.
  • The EAP comes after positive clinical outcomes in two patients with pulmonary fungal infection treated with TFF VORI on a compassionate use basis.

Global Invasive Fungal Infections Market Report 2023: Increasing Invasive Fungal Infections with Life-threatening Conditions Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, May 29, 2023
Biotechnology, Pharmaceutical, Health, Molecule, Amphotericin B, Fungal infection, Risk factor, Imidazole, Prevalence, Diabetes, HIV, Blastomycosis, Posaconazole, Infection, Candidiasis, Overalls, Isavuconazonium, Ageing, Mucormycosis, Merck & Co., Polyene, Fungemia, CDC, Incidence, AR, Patient, Developed country, ROW, Growth, Mortality, Merck, Immunodeficiency, Immunosuppression, Cryptococcus, Pfizer, Triazole, Pharmaceutical industry, Vaccine, Voriconazole, Echinocandin, Aspergillosis, Azole, Fluconazole

However, there are also antibody molecules in early preclinical development, which are currently not on the market.

Key Points: 
  • However, there are also antibody molecules in early preclinical development, which are currently not on the market.
  • The increasing use of broad-spectrum antibiotics, the aging population, and the growing prevalence of immunocompromised patients are driving the growth of invasive candidiasis.
  • By Region: The report provides insight into the invasive fungal infections market based on the geographical operations, namely North America, Europe, Asia Pacific, and ROW.
  • The North American region has emerged as a dominant player in the invasive fungal infections market, owing to several key factors.

SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 11, 2023
Workforce, GSK, FURI, Medical Affairs Bureau, Candidiasis, Partnership, SG, General Administration of Sport of China, Biotechnology, Voriconazole, Tablet, End-user license agreement, Congress, GSK plc, Antimalarial medication, ECCMID, Investment, Patient, European, License, Commercial, Research, Fluconazole, Infection, Safety, Salvage therapy, Pharmaceutical industry, Beauty salon

JERSEY CITY, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced financial results for the first quarter ended March 31, 2023.

Key Points: 
  • JERSEY CITY, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced financial results for the first quarter ended March 31, 2023.
  • On March 30, 2023, SCYNEXIS announced that the Company has entered into an exclusive agreement with GSK to commercialize and further develop BREXAFEMME® (ibrexafungerp tablets) for all indications.
  • BREXAFEMME net sales were $1.1 million in first quarter 2023 and $0.7 million in Q1 2022.
  • Cash, cash equivalents and short-term investments totaled $54.8 million on March 31, 2023, compared to $73.5 million on December 31, 2022.

LianBio Promotes Pascal Qian to Chief Commercial Officer

Retrieved on: 
Friday, April 21, 2023
Medical Affairs Bureau, Voriconazole, P&L, Novartis, Patient, Pascal, Growth, Pfizer, Pharmaceutical industry, Montelukast, Lilly

SHANGHAI, China and PRINCETON, N.J., April 21, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the promotion of Pascal Qian to the position of Chief Commercial Officer.

Key Points: 
  • SHANGHAI, China and PRINCETON, N.J., April 21, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the promotion of Pascal Qian to the position of Chief Commercial Officer.
  • “As we continue to prepare for potential mavacamten approval and launch in 2024, Pascal will oversee the significant growth of our commercial capabilities in his expanded role of Chief Commercial Officer and China General Manager,” said Yizhe Wang, Ph.D., Chief Executive Officer of LianBio.
  • In his expanded role as Chief Commercial Officer, he will lead the company’s commercial strategy and readiness, in addition to managing China operations.
  • Prior to joining LianBio, Mr. Qian served as the Vice President, Head of Oncology Business Unit, at Lilly China.

SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, March 31, 2023
Candidiasis, Public, Food and Drug Administration, Prescription, Bangladesh Technical Education Board, Chemistry, Incidence, Journal, Candida auris, Investment, Patient, Body mass index, Medicines and Healthcare products Regulatory Agency, 3B, Infection, Research, VVC, Ibrexafungerp, Diagnosis, Fungal infection, FDA, NIH, Safety, Salvage therapy, Aspergillosis, GSK, General Administration of Sport of China, Biotechnology, Voriconazole, Tablet, Mortality, Hand, MHRA, Journal of Fungi, SG, CMC, IC, NDA, Medication, Case Western Reserve University, Fungemia, Antimalarial medication, United Kingdom, Poster, Trial of the century, Fluconazole, Food, Pharmaceutical industry, Drug, Self storage, Cryptocurrency, Reinsurance, Fungus, IQVIA, FURI

GSK will make an upfront payment to SCYNEXIS of $90 million, as well as potential future milestones and tiered royalties.

Key Points: 
  • GSK will make an upfront payment to SCYNEXIS of $90 million, as well as potential future milestones and tiered royalties.
  • JERSEY CITY, N.J., March 31, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the fourth quarter and full year ended on December 31, 2022.
  • According to IQVIA data, there were 5,125 total prescriptions for BREXAFEMME written in Q4 2022, and more than 20,000 total prescriptions written in 2022.
  • The approval was based on positive results from the pivotal Phase 3 CANDLE study reported in February 2022.

Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers

Retrieved on: 
Wednesday, March 15, 2023
Research, Conference, Histoplasma capsulatum, Mortality, Fungal infection, Pseudallescheria boydii, Voriconazole, São Paulo, Amphotericin B, Immunology, USP, Gordon Research Conferences, Biology, Caspofungin, Fungal keratitis, Micafungin, World Health Organization, Fungus, Fluconazole, Cryptococcosis, OTCQB, Posaconazole, News, University, Pharmaceutical industry, Vaccine, Antibiotics, Mucorales

Extensive in vitro testing of Brilacidin by these research groups against multiple pathogenic human fungi has been completed.

Key Points: 
  • Extensive in vitro testing of Brilacidin by these research groups against multiple pathogenic human fungi has been completed.
  • USP researchers have also shown Brilacidin to be synergistic with caspofungin in different types of fungi.
  • Beyond Brilacidin’s broad-spectrum ability to directly inhibit fungal pathogens, Brilacidin may favorably modulate the host response to fungal infections.
  • Corresponding posters for these conferences are available on the Events and Presentations section of the Company’s website at the link below.

Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin’s Potential for Treating Fungal Keratitis

Retrieved on: 
Tuesday, December 13, 2022
Eye, Publishing, Posaconazole, Cryptococcus, Mycosis, Voriconazole, Cryptococcosis, Keratitis, Antifungal, Human, Orphan drug, Patient, Toxicity, Mucorales, OTCQB, Research, Mycology, Disease, Fungal keratitis, Caspofungin, University, WHO, Policy, Cornea, World Health Organization, USP, Cryptococcus neoformans, Pharmaceutical industry, Fusarium, Aspergillus

WAKEFIELD, MA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided an update on ongoing research on the broad-spectrum antifungal activity of Brilacidin, the Company’s defensin mimetic drug candidate exhibiting antimicrobial and immunomodulatory properties.

Key Points: 
  • New in vivo data in an A. fumigatus murine fungal keratitis model showed Brilacidin reduced fungal burden and disease severity, while also improving corneal thickness compared to control.
  • Worldwide, on an annual basis, fungal keratitis affects up to 1.5 million people, of whom 75 percent may lose an eye and/or their sight.
  • These new Brilacidin findings in fungal keratitis complement an earlier in vitro and in vivo evaluation of Brilacidin as an ocular anti-infective in bacterial keratitis.
  • A broad-spectrum drug that could target both fungal and bacterial keratitis would be uniquely positioned as to its treatment profile and commercial potential.